	US 11,780,910 B1
	Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
Anette Henriksen, Alleroed (DK); Thomas Nylandsted Krogh, Jyllinge (DK); Per J. Greisen, Belmont, MA (US); and Thomas Egebjerg, Ganloese (DK)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on May 2, 2023, as Appl. No. 18/142,242.
Claims priority of application No. 22171090 (EP), filed on May 2, 2022; and application No. 22201248 (EP), filed on Oct. 13, 2022.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); C07K 16/22 (2006.01); A61P 3/10 (2006.01)

CPC C07K 16/22 (2013.01) [A61P 3/10 (2018.01); A61K 2039/505 (2013.01); C07K 2317/35 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

24 Claims

1. A monovalent antibody or antigen-binding fragment thereof capable of binding human ANGPTL3 (hANGPTL3) (SEQ ID NO:1),

wherein

a) the heavy chain of said antibody or antigen-binding fragment thereof comprises:

a CDR1 sequence of amino acid residues SYWMT (SEQ ID NO:2), and

a CDR2 sequence of amino acid residues SISSHSTYIYYADSVKG (SEQ ID NO:3), and

a CDR3 sequence of amino acid residues EGWYDNWFDP (SEQ ID NO:4); or

b) the heavy chain of said antibody or antigen-binding fragment thereof comprises:

a CDR1 sequence of amino acid residues SYWMT (SEQ ID NO:24), and

a CDR2 sequence of amino acid residues SISSHSTYIYYADSVKG (SEQ ID NO:25), and

a CDR3 sequence of amino acid residues EGWYDNWNDP (SEQ ID NO:26),

and

wherein the light chain of said antibody or antigen-binding fragment thereof comprises:

a CDR1 sequence of amino acid residues RASQNIRSPYLA (SEQ ID NO:9), and

a CDR2 sequence of amino acid residues GVSSRAA (SEQ ID NO:10), and

a CDR3 sequence of amino acid residues QQYDDHPYT (SEQ ID NO:11).